Optimising the medical management of benign prostatic hyperplasia.
Marberger
Michael
M
Department of Urology, University of Vienna, Medical School, Währinger Gürtel 18-20, A-1090 Vienna, Austria. uroldep@akh-wien.ac.at
Harkaway
Richard
R
de la Rosette
Jean
J
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D042944:Cholestenone 5 alpha-Reductase / Q000037:antagonists & inhibitors; D018450:Disease Progression; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D011470:Prostatic Hyperplasia / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy*; D016896:Treatment Outcome
D000317:Adrenergic alpha-Antagonists; D042944:Cholestenone 5 alpha-Reductase